Rallybio CorpNASDAQ:RLYB
- LAST PRICE1.6700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.6600/ 15
- Ask / Lots1.6700/ 36
- Open / Previous Close0.0000 / 1.6700
- Day Range---
- 52 Week Range
- Volume11,703
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RLYB |
|---|---|---|
| 09:32 ET | 2706 | 1.8 |
| 09:36 ET | 2950 | 1.76 |
| 09:38 ET | 1000 | 1.75 |
| 09:39 ET | 1000 | 1.7591 |
| 09:45 ET | 2967 | 1.73 |
| 09:48 ET | 9140 | 1.7 |
| 09:50 ET | 1120 | 1.7 |
| 09:52 ET | 5948 | 1.72 |
| 09:54 ET | 805 | 1.7 |
| 09:56 ET | 200 | 1.7399 |
| 09:59 ET | 1350 | 1.7106 |
| 10:03 ET | 1393 | 1.71 |
| 10:08 ET | 1000 | 1.715 |
| 10:12 ET | 2813 | 1.7 |
| 10:14 ET | 8065 | 1.71 |
| 10:15 ET | 650 | 1.7123 |
| 10:17 ET | 2705 | 1.71 |
| 10:19 ET | 1100 | 1.7 |
| 10:21 ET | 486 | 1.7 |
| 10:24 ET | 253 | 1.6906 |
| 10:26 ET | 2391 | 1.68 |
| 10:28 ET | 1915 | 1.6903 |
| 10:30 ET | 1790 | 1.7 |
| 10:35 ET | 100 | 1.7 |
| 10:37 ET | 600 | 1.7051 |
| 10:39 ET | 108 | 1.7 |
| 10:42 ET | 700 | 1.71 |
| 10:44 ET | 600 | 1.7 |
| 10:46 ET | 3544 | 1.73 |
| 10:48 ET | 3721 | 1.73 |
| 10:50 ET | 2893 | 1.77 |
| 10:51 ET | 1300 | 1.76 |
| 10:53 ET | 24480 | 1.744 |
| 10:55 ET | 17216 | 1.77 |
| 11:02 ET | 715 | 1.7553 |
| 11:04 ET | 852 | 1.74 |
| 11:08 ET | 100 | 1.74 |
| 11:09 ET | 1000 | 1.755 |
| 11:13 ET | 1348 | 1.73 |
| 11:18 ET | 1218 | 1.74 |
| 11:20 ET | 100 | 1.73 |
| 11:22 ET | 1097 | 1.73 |
| 11:26 ET | 1656 | 1.73 |
| 11:27 ET | 8212 | 1.7204 |
| 11:29 ET | 100 | 1.7103 |
| 11:31 ET | 350 | 1.71 |
| 11:36 ET | 1300 | 1.73 |
| 11:38 ET | 135 | 1.73 |
| 11:42 ET | 100 | 1.735 |
| 11:51 ET | 2375 | 1.7201 |
| 11:54 ET | 9059 | 1.7399 |
| 11:56 ET | 100 | 1.73 |
| 12:02 ET | 431 | 1.73 |
| 12:03 ET | 676 | 1.7399 |
| 12:09 ET | 100 | 1.72 |
| 12:12 ET | 123 | 1.725 |
| 12:14 ET | 111 | 1.72 |
| 12:18 ET | 1455 | 1.729 |
| 12:20 ET | 1419 | 1.73 |
| 12:25 ET | 100 | 1.71 |
| 12:27 ET | 100 | 1.725 |
| 12:30 ET | 297 | 1.74 |
| 12:32 ET | 100 | 1.74 |
| 12:39 ET | 100 | 1.72 |
| 12:50 ET | 450 | 1.74 |
| 12:56 ET | 200 | 1.7275 |
| 01:01 ET | 2732 | 1.75 |
| 01:08 ET | 124 | 1.77 |
| 01:14 ET | 896 | 1.76 |
| 01:21 ET | 499 | 1.76 |
| 01:24 ET | 100 | 1.74 |
| 01:33 ET | 2339 | 1.74 |
| 01:35 ET | 784 | 1.755 |
| 01:39 ET | 307 | 1.7594 |
| 01:42 ET | 180 | 1.7593 |
| 01:46 ET | 237 | 1.745 |
| 01:48 ET | 200 | 1.74 |
| 01:50 ET | 1587 | 1.75 |
| 01:51 ET | 300 | 1.76 |
| 01:53 ET | 8516 | 1.74 |
| 02:06 ET | 100 | 1.74 |
| 02:08 ET | 1050 | 1.73 |
| 02:09 ET | 339 | 1.73 |
| 02:15 ET | 100 | 1.73 |
| 02:22 ET | 100 | 1.73 |
| 02:29 ET | 300 | 1.73 |
| 02:33 ET | 5923 | 1.7 |
| 02:36 ET | 100 | 1.69 |
| 02:40 ET | 770 | 1.72 |
| 02:44 ET | 571 | 1.73 |
| 02:45 ET | 100 | 1.7 |
| 03:00 ET | 1100 | 1.72 |
| 03:02 ET | 1120 | 1.72 |
| 03:09 ET | 139 | 1.729 |
| 03:21 ET | 3049 | 1.7 |
| 03:32 ET | 223 | 1.7136 |
| 03:34 ET | 170 | 1.716 |
| 03:38 ET | 3000 | 1.7142 |
| 03:41 ET | 414 | 1.715 |
| 03:43 ET | 7102 | 1.71 |
| 03:45 ET | 375 | 1.715 |
| 03:48 ET | 3146 | 1.715 |
| 03:52 ET | 430 | 1.715 |
| 03:54 ET | 4523 | 1.73 |
| 03:56 ET | 8953 | 1.705 |
| 03:57 ET | 21165 | 1.68 |
| 03:59 ET | 76913 | 1.67 |
Yesterday
Apr 17, 2024
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting, from 4:01PM ET on Wednesday Apr 17, 2024 by Dow Jones
4:01PM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 11, 2024
DJ Rallybio Is Maintained at Outperform by Wedbush, from 10:11AM ET on Thursday Apr 11, 2024 by Dow Jones
10:11AM ET on Thursday Apr 11, 2024 by Dow Jones
Apr 10, 2024
DJ Rallybio Shares Rise 30% on Investment From J&J, Collaboration, from 5:12PM ET on Wednesday Apr 10, 2024 by Dow Jones
5:12PM ET on Wednesday Apr 10, 2024 by Dow JonesRallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), from 4:01PM ET on Wednesday Apr 10, 2024 by Dow Jones
4:01PM ET on Wednesday Apr 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Rallybio Corp | 63.1M | -0.9x | --- |
enVVeno Medical Corp | 63.7M | -2.4x | --- |
RetinalGenix Technologies Inc | 62.2M | -29.1x | --- |
Lantern Pharma Inc | 62.0M | -3.9x | --- |
OKYO Pharma Ltd | 49.5M | -0.1x | --- |
Ocean Biomedical Inc | 65.0M | -1.3x | --- |
Company Information
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
Contact Information
- Headquarters
- 234 CHURCH STREET, SUITE 1020NEW HAVEN, CT, United States 06510
- Phone
- 203-859-3820
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Martin Mackay
- President, Chief Executive Officer, Director
- Stephen Uden
- Chief Financial Officer, Treasurer
- Jonathan Lieber
- Chief Medical Officer
- Steven Ryder
- Independent Director
- Helen Boudreau
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $63.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 37.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.84 |
Book Value | $2.81 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
